PALLAS: PALbociclib CoLlaborative Adjuvant Study
Brief description of study
The purpose of this study is to compare any good and bad effects of using 2 years of the investigational drug Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood that invasive breast cancer returns.
Detailed description of study
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast cancer, breast, hormone
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
31 Jan 2020.
Study ID: 825836
